BNTCW
Benitec Biopharma Limited
stock NASDAQ

Benitec Biopharma Ltd. engages in the development of therapeutics based on patented gene silencing technology called ddRNAi. It develops treatments for chronic and life threatening human conditions, such as oculopharyngeal muscular dystrophy, oncology, wet age-related macular degeneration, and hepatitis B. It operates through the Australia and USA geographical segments. The company was founded by Kenneth C. Reed in 1997 and is headquartered in North Sydney, Australia.